Product guide · Restricted substance

GynSyn Labs Relief BPC-157 60 caps

Peptide product from GynSyn Labs, 60 capsules. This guide sets out what the manufacturer states about the composition of GynSyn Labs Relief BPC-157 60 caps, what independent research says about its main ingredient, and the safety and regulatory points that apply. It contains substances that are not authorised as food or medicine in the EU. This guide is educational: it does not recommend use and gives no directions for use.

Educational guide · Sources checked 4 November 2026 · 9 references

Back to the product

Named ingredients: 1
Amounts stated: None
Status: Restricted substance
Evidence summaries: 1

Overview

Manufacturer information

GynSyn Labs Relief BPC-157 60 caps contains BPC-157. Each pack holds 60 capsules. The strength is not stated in the product data.

Ingredients & composition

Manufacturer information

Ingredient	Amount
BPC-157	Not stated

The manufacturer does not state the amount of any ingredient. Without amounts, the research summarised in this guide cannot be related to this product's dose.

Scientific background

Independent research

BPC-157

BPC-157 ("body protection compound") is a synthetic peptide of 15 amino acids, derived from a sequence of a protein in human gastric juice. It is studied for tissue healing¹.

Research evidence

Independent research

BPC-157

Most research on BPC-157 consists of animal and cell studies reporting effects on tendon, ligament, muscle and gut healing¹².

A 2026 systematic review found only three small human studies: a retrospective study of knee injections, a pilot study in interstitial cystitis and a two-person intravenous safety study. All were of poor methodological quality, and the overall certainty of evidence was very low³⁴.

Evidence limitations

Independent research

This product does not state all ingredient amounts, so the doses used in research cannot be compared with what one serving provides.

No published study has tested this specific product; the research summarised here concerns the ingredient itself.

BPC-157

Reviewers conclude that well-designed human trials are needed to assess safety and efficacy, and that BPC-157 should not be used clinically in humans outside ethically approved, regulated trials³².

Safety & potential risks

Independent research

BPC-157

Human safety data are minimal. Reviewers highlight risks from unregulated manufacturing and contamination, and unknown clinical safety⁵. The US FDA placed BPC-157 among bulk substances that may present significant safety risks in compounding, citing possible immunogenicity and peptide impurities⁶.

Regulatory status

GIGACULT product information

Contains a peptide that is not authorised as food (including food supplements) or as a medicinal product in the EU. No dosing information for human use is provided.

Regulation and sport

BPC-157

BPC-157 is not authorised as a medicine or as a food in the EU⁷⁸. The World Anti-Doping Agency prohibits non-approved substances such as BPC-157 at all times⁹.

Scientific references

Józwiak M, Bauer M, Kamysz W, et al. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. Pharmaceuticals (Basel). 2025;18:185. PubMed 40005999
McGuire FP, Martinez R, Lenz A, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18:611-619. PubMed 40789979
Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92. PubMed 42885452
Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27:8-13. PubMed 34324435
Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21:485-495. PubMed 40756949
US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (lists BPC-157). Source
Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union. Source
Regulation (EU) 2015/2283 on novel foods. Official Journal of the European Union. Source
World Anti-Doping Agency. The Prohibited List (current edition). Source

Sources checked against PubMed, Crossref or the official publisher on 2026-11-04. Manufacturer information is taken from the product's own data and has not been independently tested.

The product